LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Elenco Azioni・MacroGenics Inc

MacroGenics Inc

Chiusa

SettoreSettore sanitario

4.21 1.94

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.18

Massimo

4.28

Metriche Chiave
By Trading Economics
Entrata	-31M -14M
Vendite	-32M 41M
EPS	-0.22
Margine di Profitto	-34.333
Dipendenti	293
EBITDA	-37M -15M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+52.16% upside

Dividendi
By Dow Jones
Utili prossimi	19 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	65M 188M
Apertura precedente	2.27
Chiusura precedente	4.21

Notizie sul Sentiment di mercato

By Acuity

75%

25%

319 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

1.47 / 1.64 Supporto e resistenza

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 mag 2026, 22:47 UTC

Azioni calde

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mag 2026, 22:16 UTC

Acquisizioni, Fusioni, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mag 2026, 22:00 UTC

I principali Market Mover

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mag 2026, 18:09 UTC

I principali Market Mover

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 mag 2026, 16:02 UTC

Utili

I principali Market Mover

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 mag 2026, 14:55 UTC

I principali Market Mover

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 mag 2026, 14:43 UTC

I principali Market Mover

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 mag 2026, 22:17 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:59 UTC

Acquisizioni, Fusioni, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mag 2026, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mag 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mag 2026, 21:16 UTC

Discorsi di Mercato

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

15 mag 2026, 20:19 UTC

Azioni calde

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mag 2026, 19:41 UTC

Acquisizioni, Fusioni, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mag 2026, 19:35 UTC

Discorsi di Mercato

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mag 2026, 19:33 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mag 2026, 18:35 UTC

Utili

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 mag 2026, 17:28 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 mag 2026, 16:50 UTC

Acquisizioni, Fusioni, Takeovers

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 mag 2026, 16:24 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 mag 2026, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

15 mag 2026, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

15 mag 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

15 mag 2026, 15:55 UTC

Discorsi di Mercato

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 mag 2026, 15:20 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 mag 2026, 15:20 UTC

Discorsi di Mercato

Silver Plunges on Inflation Worries -- Market Talk

15 mag 2026, 15:20 UTC

Utili

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 mag 2026, 14:33 UTC

Discorsi di Mercato

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

52.16% in crescita

Previsioni per 12 mesi

Media 6.33 USD 52.16%

Alto 9 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a MacroGenics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.47 / 1.64Supporto e resistenza

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

319 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.